Genmab A/S Genmab Announces The Nomination Of A New Member Of The Company's Board Of Directors
14 March 2022 - 11:47PM
UK Regulatory
TIDMGEN
Company Announcement
-- Genmab's Board of Directors proposes that Elizabeth O'Farrell is elected
as a new member of the Board of Directors
COPENHAGEN, Denmark; March 14, 2022 --
https://www.globenewswire.com/Tracker?data=Ej6eJPsHij7-c7JK2piPocJhVzFpnLZjBbq-XHT8dsKXs3dUJ3N6rr7LgQmbEhSebo9IccVjR6VGq7OeAmhwxw==
Genmab A/S (Nasdaq: GMAB) announced today that the Company's Board
of Directors nominates Elizabeth O'Farrell for election as a new
member of the Board of Directors at the Annual General Meeting,
which will be held on March 29, 2022.
The Board of Directors initiated a replacement process for a
candidate to replace Jonathan Peacock who stepped down from the
Board of Directors last year. Following a comprehensive process,
the Board of Directors nominates Elizabeth O'Farrell for election
to the Genmab Board of Directors for a one year period in addition
to the nomination of the current members of the Board of Directors
for re-election on agenda item 5 of the summons for the Annual
General Meeting, including Appendix 1: Candidates for the Board of
Directors.
About Elizabeth O'Farrell
Female, American, 58
Independent
Special Competencies
During her 24-year career at Eli Lilly, Ms. O'Farrell served as
CFO of some of the company's largest businesses including as Head
of Global Finance Operations. She has solid financial experience
including strategic, operational and financial decision-making and
reporting across the value chain as well as expertise in driving
global change initiatives. Ms. O'Farrell led cross-functional teams
and drove paradigm changing contributions within finance and across
Eli Lilly through collaboration, relationship and persuasive
influence in addition to championing transformative business and
culture changes. Most recently she served as Chief Procurement
Officer and Global Head of Shared Services at Eli Lilly. Ms.
O'Farrell also has served roles at Price Waterhouse Coopers and
Whipple & Company Corporation. She completed her Bachelor of
Science in Accounting with Honors and an MBA, Management
Information Systems, from Indiana University, Bloomington.
Current Board Positions
Chair: PDL BioPharma*(1)
Member: LENSAR(2) , Geron Corporation(3) , Inhibikase
Therapeutics(4)
1. Chair of Compensation Committee, Member of Audit Committee,
Member of Cost Committee
2. Chair of Audit Committee
3. Chair of Audit Committee
4. Chair of Audit Committee, Member of Compensation
Committee
*Companies marked with an asterisk (*) are non-public
companies.
About Genmab
Genmab is an international biotechnology company with a core
purpose to improve the lives of people with cancer. For more than
20 years, Genmab's vision to transform cancer treatment has driven
its passionate, innovative and collaborative teams to invent
next-generation antibody technology platforms and leverage
translational research and data sciences, fueling multiple
differentiated cancer treatments that make an impact on people's
lives. To develop and deliver novel therapies to patients, Genmab
has formed 20+ strategic partnerships with biotechnology and
pharmaceutical companies. Genmab's proprietary pipeline includes
bispecific T-cell engagers, next-generation immune checkpoint
modulators, effector function enhanced antibodies and antibody-drug
conjugates.
Genmab is headquartered in Copenhagen, Denmark with locations in
Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo,
Japan. For more information, please visit Genmab.com
https://www.globenewswire.com/Tracker?data=Ej6eJPsHij7-c7JK2piPoZWmf1R1Yn2aZcUYJqf6ByvtdD4GHKEl3jZIKQ41tzvjb1INCISlWy8sNpDrb4wyGg==
and follow us on Twitter.com/Genmab
https://www.globenewswire.com/Tracker?data=3u6wmj-YCEOu4M-CjtjbaV1kEsm9khBdRH5ZMEyLcFdEiE9gqgd7CwNrKAPrr8Y2deQ-_o5X7ZA95h0ws-V6M63p3rrCA56n_309g0FXIB8=
.
Contact:
Marisol Peron, Senior Vice President, Global Investor Relations
& Communications
T: +1 609 524 0065; E: mmp@genmab.com
https://www.globenewswire.com/Tracker?data=LxHdQSGrrk1E37-en78B9KbrWoTAgM39JV4IbRYOsqHGQ6YK8nuFBd_g87Df1IAaxEKs8qHdV6YyeblCkP8WPQ==
For Investor Relations:
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
https://www.globenewswire.com/Tracker?data=B3ckgYCwzHZzCS57RJKmngI9SDEe3H7bF2_tcJJ9gdx-iWlJ46T_3FtcNM-5Mw306cp-1vCwgkj7NgNLKXIC5g==
This Company Announcement contains forward looking statements.
The words "believe", "expect", "anticipate", "intend" and "plan"
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab's most recent financial reports, which are
available on
https://www.globenewswire.com/Tracker?data=47ok8Mw0o_zndLvOYWTSxm19J4Na4LqTLFINJigUTzdzuoTc3M6hQcXJCkwLcnyuJRt2QSD5DpN7LkbQIu_p1g==
www.genmab.com and the risk factors included in Genmab's most
recent Annual Report on Form 20-F and other filings with the U.S.
Securities and Exchange Commission (SEC), which are available at
https://www.globenewswire.com/Tracker?data=47ok8Mw0o_zndLvOYWTSxm_hoXzlXQqjFpb5wciHvM3txOaoQJIiOjYbEAGrf3ITVKgxDXojAbdWUaAUlpJ__BElfAmxkZJEI_aQzvQ78bc=
www.sec.gov. Genmab does not undertake any obligation to update or
revise forward looking statements in this Company Announcement nor
to confirm such statements to reflect subsequent events or
circumstances after the date made or in relation to actual results,
unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks:
Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination
with the Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ; DuoBody
in combination with the DuoBody logo(R) ; HexaBody(R) ; HexaBody in
combination with the HexaBody logo(R) ; DuoHexaBody(R) and
HexElect(R) .
Company Announcement no. 10
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Attachment
-- 140322_CA10_Board Nomination
https://ml-eu.globenewswire.com/Resource/Download/8091ad00-e312-4528-b5b2-b762b32885bf
(END) Dow Jones Newswires
March 14, 2022 08:47 ET (12:47 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Genuit (LSE:GEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genuit (LSE:GEN)
Historical Stock Chart
From Apr 2023 to Apr 2024